International Journal of Infection

Published by: Kowsar

Diagnostic Plausibility of MTBDRplus and MTBDRsl Line Probe Assays for Rapid Drug Susceptibility Testing of Drug Resistant Mycobacterium tuberculosis Strains in Pakistan

Mona Javaid 1 , Altaf Ahmed 1 , * , Sunil Asif 1 and Afsheen Raza 1
Authors Information
1 The Indus Hospital, Karachi, Pakistan
Article information
  • International Journal of Infection: July 01, 2016, 3 (3); e34903
  • Published Online: June 25, 2016
  • Article Type: Research Article
  • Received: December 8, 2015
  • Revised: December 27, 2015
  • Accepted: December 27, 2015
  • DOI: 10.17795/iji-34903

To Cite: Javaid M, Ahmed A, Asif S, Raza A. Diagnostic Plausibility of MTBDRplus and MTBDRsl Line Probe Assays for Rapid Drug Susceptibility Testing of Drug Resistant Mycobacterium tuberculosis Strains in Pakistan, Int J Infect. 2016 ; 3(3):e34903. doi: 10.17795/iji-34903.

Copyright © 2016, Infectious Diseases and Tropical Medicine Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. World Health Organization . Global Tuberculosis Report 2014. 2014;
  • 2. World Health Organization . WHO EMRO Stop TB Programmes, Pakistan. 2015;
  • 3. Ali A, Hasan Z, McNerney R, Mallard K, Hill-Cawthorne G, Coll F, et al. Whole genome sequencing based characterization of extensively drug-resistant Mycobacterium tuberculosis isolates from Pakistan. PLoS One. 2015; 10(2): 117771[DOI][PubMed]
  • 4. Hasan R, Jabeen K, Ali A, Rafiq Y, Laiq R, Malik B, et al. Extensively drug-resistant tuberculosis, Pakistan. Emerg Infect Dis. 2010; 16(9): 1473-5[DOI][PubMed]
  • 5. World Health Organization . Molecular Line Probe Assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). 2008;
  • 6. World Health Organization . Use of liquid TB culture and drug susceptibility testing (DST) in low and medium income countries: Summary report of the expert group meeting on the use of liquid culture media: Summary report of the expert group meeting on the use of liquid culture media. 2007;
  • 7. Anek-Vorapong R, Sinthuwattanawibool C, Podewils LJ, McCarthy K, Ngamlert K, Promsarin B, et al. Validation of the GenoType MTBDRplus assay for detection of MDR-TB in a public health laboratory in Thailand. BMC Infect Dis. 2010; 10: 123[DOI][PubMed]
  • 8. Felkel M, Exner R, Schleucher R, Lay H, Autenrieth IB, Kempf VA, et al. Evaluation of Mycobacterium tuberculosis drug susceptibility in clinical specimens from Nigeria using genotype MTBDRplus and MTBDRsl assays. Eur J Microbiol Immunol (Bp). 2013; 3(4): 252-7[DOI][PubMed]
  • 9. Hillemann D, Rusch-Gerdes S, Richter E. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol. 2009; 47(6): 1767-72[DOI][PubMed]
  • 10. Kiet VS, Lan NT, An DD, Dung NH, Hoa DV, van Vinh Chau N, et al. Evaluation of the MTBDRsl test for detection of second-line-drug resistance in Mycobacterium tuberculosis. J Clin Microbiol. 2010; 48(8): 2934-9[DOI][PubMed]
  • 11. Jabeen K, Shakoor S, Hasan R. Fluoroquinolone-resistant tuberculosis: implications in settings with weak healthcare systems. Int J Infect Dis. 2015; 32: 118-23[DOI][PubMed]
  • 12. Farooqi JQ, Khan E, Alam SM, Ali A, Hasan Z, Hasan R. Line probe assay for detection of rifampicin and isoniazid resistant tuberculosis in Pakistan. J Pak Med Assoc. 2012; 62(8): 767-72[PubMed]
  • 13. Idrees F, Irfan M, Jabeen K, Hasan R. Genotype MTBDR plus Line Probe Assay as a rapid tool for the diagnosis of smear-negative tuberculosis in bronchoalveolar lavage fluid in Pakistan. Eur Respir J. 2014; 44(58): 2693
  • 14. Irfan M, Jabeen K, Shahzad H, Zubairi ABS, Hasan R. Evaluation of sensitivity and specificity of GenoType MTBDRplus line probe assay in rapid diagnosis of tuberculous pleural effusion. Int J Mycobacteriol. 2015; 4: 111
  • 15. Munir MK, Anwer N, Iqbal R, Nosheen S, Rehman S, Salam AA. Comparison of Genotype MTBDRplus Testing Kit with conventional method for Drug Susceptibility Testing of Isoniazid and Rifampicin in Tuberculosis Patients. Pak J Med Sci. 2014; 53(2): 25
  • 16. Kent PKG. Public health mycobacteriology: a guide for the level III laboratory. 1985;
  • 17. Crudu V, Stratan E, Romancenco E, Allerheiligen V, Hillemann A, Moraru N. First evaluation of an improved assay for molecular genetic detection of tuberculosis as well as rifampin and isoniazid resistances. J Clin Microbiol. 2012; 50(4): 1264-9[DOI][PubMed]
  • 18. Dheda K, Warren RM, Zumla A, Grobusch MP. Extensively drug-resistant tuberculosis: epidemiology and management challenges. Infect Dis Clin North Am. 2010; 24(3): 705-25[DOI][PubMed]
  • 19. Brossier F, Veziris N, Aubry A, Jarlier V, Sougakoff W. Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates. J Clin Microbiol. 2010; 48(5): 1683-9[DOI][PubMed]
  • 20. Kontsevaya I, Mironova S, Nikolayevskyy V, Balabanova Y, Mitchell S, Drobniewski F. Evaluation of two molecular assays for rapid detection of mycobacterium tuberculosis resistance to fluoroquinolones in high-tuberculosis and -multidrug-resistance Settings. J Clin Microbiol. 2011; 49(8): 2832-7[DOI][PubMed]
  • 21. Wang JY, Lee LN, Lai HC, Wang SK, Jan IS, Yu CJ, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J Antimicrob Chemother. 2007; 59(5): 860-5[DOI][PubMed]
  • 22. Qazi O, Rahman H, Tahir Z, Qasim M, Khan S, Ahmad Anjum A, et al. Mutation pattern in rifampicin resistance determining region of rpoB gene in multidrug-resistant Mycobacterium tuberculosis isolates from Pakistan. Int J Mycobacteriol. 2014; 3(3): 173-7[DOI][PubMed]
  • 23. Ahmad S, Al-Mutairi NM, Mokaddas E. Variations in the occurrence of specific rpoB mutations in rifampicin-resistant Mycobacterium tuberculosis isolates from patients of different ethnic groups in Kuwait. Indian J Med Res. 2012; 135(5): 756-62[PubMed]
  • 24. Brown TJ, Herrera-Leon L, Anthony RM, Drobniewski FA. The use of macroarrays for the identification of MDR Mycobacterium tuberculosis. J Microbiol Methods. 2006; 65(2): 294-300[DOI][PubMed]
  • 25. Gagneux S. Fitness cost of drug resistance in Mycobacterium tuberculosis. Clin Microbiol Infect. 2009; 15 Suppl 1: 66-8[DOI][PubMed]
  • 26. Gagneux S, Burgos MV, DeRiemer K, Encisco A, Munoz S, Hopewell PC, et al. Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis. PLoS Pathog. 2006; 2(6)[DOI][PubMed]
  • 27. Mariam DH, Mengistu Y, Hoffner SE, Andersson DI. Effect of rpoB mutations conferring rifampin resistance on fitness of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2004; 48(4): 1289-94[PubMed]
  • 28. Morlock GP, Plikaytis BB, Crawford JT. Characterization of spontaneous, In vitro-selected, rifampin-resistant mutants of Mycobacterium tuberculosis strain H37Rv. Antimicrob Agents Chemother. 2000; 44(12): 3298-301[PubMed]
  • 29. Yuen LK, Leslie D, Coloe PJ. Bacteriological and molecular analysis of rifampin-resistant Mycobacterium tuberculosis strains isolated in Australia. J Clin Microbiol. 1999; 37(12): 3844-50[PubMed]
  • 30. Bang D, Andersen PH, Andersen AB, Thomsen VO. Isoniazid-resistant tuberculosis in Denmark: mutations, transmission and treatment outcome. J Infect. 2010; 60(6): 452-7[DOI][PubMed]
  • 31. Cattamanchi A, Dantes RB, Metcalfe JZ, Jarlsberg LG, Grinsdale J, Kawamura LM, et al. Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis. Clin Infect Dis. 2009; 48(2): 179-85[DOI][PubMed]
  • 32. Jacobson KR, Theron D, Victor TC, Streicher EM, Warren RM, Murray MB. Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa. Clin Infect Dis. 2011; 53(4): 369-72[DOI][PubMed]
  • 33. Menzies D, Benedetti A, Paydar A, Royce S, Madhukar P, Burman W, et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med. 2009; 6(9): 1000150[PubMed]
  • 34. Kurbatova EV, Cavanaugh JS, Shah NS, Wright A, Kim H, Metchock B, et al. Rifampicin-resistant Mycobacterium tuberculosis: susceptibility to isoniazid and other anti-tuberculosis drugs. Int J Tuberc Lung Dis. 2012; 16(3): 355-7[DOI][PubMed]
  • 35. Smith SE, Kurbatova EV, Cavanaugh JS, Cegielski JP. Global isoniazid resistance patterns in rifampin-resistant and rifampin-susceptible tuberculosis. Int J Tuberc Lung Dis. 2012; 16(2): 203-5[DOI][PubMed]
  • 36. Lacoma A, Garcia-Sierra N, Prat C, Maldonado J, Ruiz-Manzano J, Haba L, et al. GenoType MTBDRsl for molecular detection of second-line-drug and ethambutol resistance in Mycobacterium tuberculosis strains and clinical samples. J Clin Microbiol. 2012; 50(1): 30-6[DOI][PubMed]
  • 37. Richter E, Rusch-Gerdes S, Hillemann D. Drug-susceptibility testing in TB: current status and future prospects. Expert Rev Respir Med. 2009; 3(5): 497-510[DOI][PubMed]
  • 38. Rigouts L, Gumusboga M, de Rijk WB, Nduwamahoro E, Uwizeye C, de Jong B, et al. Rifampin resistance missed in automated liquid culture system for Mycobacterium tuberculosis isolates with specific rpoB mutations. J Clin Microbiol. 2013; 51(8): 2641-5[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments